<DOC>
	<DOC>NCT02365207</DOC>
	<brief_summary>Patients with invasive bladder cancer will be given 3-6 treatments (based on treatment response) BCG intravesically followed by a cystectomy.</brief_summary>
	<brief_title>Intravesical BCG Administration to Patients With Invasive Bladder Cancer</brief_title>
	<detailed_description>Patients with muscle invasive (≥T1) bladder cancer will be given 3-6 treatments (based on treatment response) intravesical TICE® BCG. BCG is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis. After completion of BCG treatments the patient will undergo a cystectomy. A portion of bladder tumor tissue and lymph nodes will be collected for research purposes during the cystectomy.</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>1. Have suspected or known invasive (≥T1) bladder cancer 2. Be able to give informed consent 3. Be age 18 or older 4. Not be in an immunosuppressed state (e.g. HIV+, use of chronic steroids &gt;1 month) 1. Have noninvasive (&lt;T1) bladder cancer 2. Unable to give informed consent 3. &lt; 18 or older 4. Is in an immunosuppressed state (e.g. HIV+, use of chronic steroids &gt;1 month)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>